| CASE REPORT |
|
| Year : 2020 | Volume
: 21
| Issue : 4 | Page : 291-295 |
|
|
The use of low-dose intermittent levosimendan infusion therapy as bridge-to-left ventricular assist device in advanced chronic heart failure secondary to isolated cardiac sarcoidosis
Kamla Al-Wahaibi1, Osman Mohamed Elfadil2
1 Tallaght University Hospital, Dublin, Ireland
2 Mayo Clinic, Rochester, MN, USA
Correspondence Address:
Dr. Osman Mohamed Elfadil
Mayo Clinic Minnesota, Rochester, MN 55901
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_85_20
|
|
|
Heart failure (HF) is a progressive condition that usually involves a debilitating late course with poor health-related quality of life and increasing mortality rate. In this report, we demonstrate the efficacy and safety of intermittent levosimendan infusion as a bridging therapy to left ventricular assist device use in a patient suffering from cardiac sarcoidosis who failed to respond to optimized medical therapy. Levosimendan was administered in an outpatient infusion-therapy facility every 2 weeks as a single intravenous infusion over 6 h at dose and rate of 0.2 μg/kg/min not proceeded by a bolus. The primary observation we are reporting is the efficacy of this approach reflected on serum concentrations of N-terminal brain natriuretic propeptide and creatinine levels. Secondary observation comprised patient-reported outcomes and clinical events including hospitalization (s).
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
